IDEAYA Biosciences (IDYA) Operating Expenses (2018 - 2026)

IDEAYA Biosciences has reported Operating Expenses for 9 years, with the latest figure at $115.1 million in Q1 2026.

• Quarterly Operating Expenses rose 36.4% year-over-year to $115.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.7 million (up 11.27% YoY) and the FY2025 annual result came in at $378.0 million, up 13.19% from the prior year.
• Operating Expenses climbed to $115.1 million in Q1 2026 per IDYA's latest filing, from $105.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $151.1 million in Q4 2024 and troughed at $25.6 million in Q1 2022.
• A 5-year average of $64.6 million and a median of $51.0 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 229.71% in 2024, then slumped 30.23% in 2025.
• Over 5 years, Operating Expenses stood at $30.5 million in 2022, then surged by 50.46% to $45.8 million in 2023, then soared by 229.71% to $151.1 million in 2024, then plunged by 30.23% to $105.4 million in 2025, then grew by 9.16% to $115.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $115.1 million, $105.4 million, and $99.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.